Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer

Shinya Asatani; Tatsuo Kanda; Masayuki Honda; Tomotaka Ishii; Yoichiro Yamana; Tomohiro Kaneko; Taku Mizutani; Hiroshi Takahashi; Mariko Kumagawa; Reina Sasaki; Ryota Masuzaki; Shini Kanezawa; Naoki Matsumoto; Kazushige Nirei; Hiroaki Yamagami; Mitsuhiko Moriyama

doi:10.1002/jgh3.12554

Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer

Shinya Asatani, Tatsuo Kanda, Masayuki Honda, Tomotaka Ishii, Yoichiro Yamana, Tomohiro Kaneko, Taku Mizutani, Hiroshi Takahashi, Mariko Kumagawa, Reina Sasaki, Ryota Masuzaki, Shini Kanezawa, Naoki Matsumoto, Kazushige Nirei, Hiroaki Yamagami, Mitsuhiko Moriyama

School of Medicine

Nihon University

Research output: Contribution to journal › Article › peer-review

Abstract

Recently, the use of immune checkpoint inhibitors (ICIs) with or without chemotherapeutic agents has been increasing in the treatment for advanced cancer. Here, we report the occurrence of liver failure after the use of pembrolizumab in an 82-year-old woman with metastatic liver disease derived from right advanced renal pelvis, ureteral cancer, and bladder cancer. She was successfully treated with 0.6 mg/kg daily prednisolone. In patients treated with ICIs, ICI-induced hepatitis is occasionally observed. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment. This is a first report of pembrolizumab-induced liver failure in elder patient with age over 80 years. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment.

Original language	English
Pages (from-to)	722-724
Number of pages	3
Journal	JGH Open
Volume	5
Issue number	6
DOIs	https://doi.org/10.1002/jgh3.12554
Publication status	Published - Jun 2021

Keywords

hepatitis
immune-related adverse event
pembrolizumab
renal pelvis and ureteral cancer
steroid

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jgh3.12554

Cite this

Asatani, S., Kanda, T., Honda, M., Ishii, T., Yamana, Y., Kaneko, T., Mizutani, T., Takahashi, H., Kumagawa, M., Sasaki, R., Masuzaki, R., Kanezawa, S., Matsumoto, N., Nirei, K., Yamagami, H., & Moriyama, M. (2021). Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer. JGH Open, 5(6), 722-724. https://doi.org/10.1002/jgh3.12554

@article{341f4d4c2199435182bcd789cda26673,

title = "Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer",

abstract = "Recently, the use of immune checkpoint inhibitors (ICIs) with or without chemotherapeutic agents has been increasing in the treatment for advanced cancer. Here, we report the occurrence of liver failure after the use of pembrolizumab in an 82-year-old woman with metastatic liver disease derived from right advanced renal pelvis, ureteral cancer, and bladder cancer. She was successfully treated with 0.6 mg/kg daily prednisolone. In patients treated with ICIs, ICI-induced hepatitis is occasionally observed. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment. This is a first report of pembrolizumab-induced liver failure in elder patient with age over 80 years. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment.",

keywords = "hepatitis, immune-related adverse event, pembrolizumab, renal pelvis and ureteral cancer, steroid",

author = "Shinya Asatani and Tatsuo Kanda and Masayuki Honda and Tomotaka Ishii and Yoichiro Yamana and Tomohiro Kaneko and Taku Mizutani and Hiroshi Takahashi and Mariko Kumagawa and Reina Sasaki and Ryota Masuzaki and Shini Kanezawa and Naoki Matsumoto and Kazushige Nirei and Hiroaki Yamagami and Mitsuhiko Moriyama",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.",

year = "2021",

month = jun,

doi = "10.1002/jgh3.12554",

language = "English",

volume = "5",

pages = "722--724",

journal = "JGH Open",

issn = "2397-9070",

publisher = "John Wiley & Sons Inc.",

number = "6",

}

Asatani, S, Kanda, T, Honda, M, Ishii, T, Yamana, Y, Kaneko, T, Mizutani, T, Takahashi, H, Kumagawa, M, Sasaki, R, Masuzaki, R, Kanezawa, S, Matsumoto, N, Nirei, K, Yamagami, H & Moriyama, M 2021, 'Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer', JGH Open, vol. 5, no. 6, pp. 722-724. https://doi.org/10.1002/jgh3.12554

TY - JOUR

T1 - Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer

AU - Asatani, Shinya

AU - Kanda, Tatsuo

AU - Honda, Masayuki

AU - Ishii, Tomotaka

AU - Yamana, Yoichiro

AU - Kaneko, Tomohiro

AU - Mizutani, Taku

AU - Takahashi, Hiroshi

AU - Kumagawa, Mariko

AU - Sasaki, Reina

AU - Masuzaki, Ryota

AU - Kanezawa, Shini

AU - Matsumoto, Naoki

AU - Nirei, Kazushige

AU - Yamagami, Hiroaki

AU - Moriyama, Mitsuhiko

PY - 2021/6

Y1 - 2021/6

N2 - Recently, the use of immune checkpoint inhibitors (ICIs) with or without chemotherapeutic agents has been increasing in the treatment for advanced cancer. Here, we report the occurrence of liver failure after the use of pembrolizumab in an 82-year-old woman with metastatic liver disease derived from right advanced renal pelvis, ureteral cancer, and bladder cancer. She was successfully treated with 0.6 mg/kg daily prednisolone. In patients treated with ICIs, ICI-induced hepatitis is occasionally observed. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment. This is a first report of pembrolizumab-induced liver failure in elder patient with age over 80 years. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment.

AB - Recently, the use of immune checkpoint inhibitors (ICIs) with or without chemotherapeutic agents has been increasing in the treatment for advanced cancer. Here, we report the occurrence of liver failure after the use of pembrolizumab in an 82-year-old woman with metastatic liver disease derived from right advanced renal pelvis, ureteral cancer, and bladder cancer. She was successfully treated with 0.6 mg/kg daily prednisolone. In patients treated with ICIs, ICI-induced hepatitis is occasionally observed. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment. This is a first report of pembrolizumab-induced liver failure in elder patient with age over 80 years. Even if patients are older, it appears important to diagnose and treat ICI-induced hepatitis earlier by multidisciplinary therapies including steroid treatment.

KW - hepatitis

KW - immune-related adverse event

KW - pembrolizumab

KW - renal pelvis and ureteral cancer

KW - steroid

UR - http://www.scopus.com/inward/record.url?scp=85105225669&partnerID=8YFLogxK

U2 - 10.1002/jgh3.12554

DO - 10.1002/jgh3.12554

M3 - Article

AN - SCOPUS:85105225669

SN - 2397-9070

VL - 5

SP - 722

EP - 724

JO - JGH Open

JF - JGH Open

IS - 6

ER -

Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this